Has Leonardo Aponte received payments from drug or device companies?

Yes. Drug and device makers reported $1,784 in general payments to Leonardo Aponte across 107 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Leonardo Aponte did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Leonardo Aponte come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Leonardo Aponte

Family Medicine · Milwaukee, WINPI 1811970833

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 29.7% of the total. Among family medicine clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,784in general payments, 2019–2025

Across 107 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$530
Boehringer Ingelheim$260
Gilead$215
Sanofi-aventis U.S. LLC$125
Takeda Pharmaceuticals U.S.A., Inc.$115
Alkermes, Inc.$104
plus $435 from 13 others

What the payments were for

Food & beverage$1,784100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	27	$530
Boehringer Ingelheim	18	$260
Gilead	7	$215
Sanofi-aventis U.S. LLC	7	$125
Takeda Pharmaceuticals U.S.A., Inc.	13	$115
Alkermes, Inc.	6	$104
Ironshore Pharmaceuticals Inc.	4	$69
Lilly USA, LLC	4	$56
Johnson & Johnson	3	$44
Melinta Therapeutics, LLC	2	$40
Pfizer	2	$40
Novo Nordisk	2	$32
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$31
Shire North American Group Inc	2	$27
MDD US Operations, LLC	2	$26
Merck	2	$25
AbbVie	2	$24
Sanofi Pasteur Inc.	1	$18
Ultragenyx Pharmaceutical Inc.	1	$4

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,784 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin →

Other family medicine in Milwaukee

William PalinMilwaukee$693K
Steven BondowMilwaukee$34K
Suresh MisraMilwaukee$16K
Ramneet BhathalMilwaukee$12K
Roland WillockMilwaukee$7K
Arthur MinesMilwaukee$6K
Jennifer ParsleyElk Mound$1.4M
Ryan AndrewsStevens Point$429K
Tara DallDelafield$230K
Mark JensonGreen Bay$204K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →